10-K: AEXA 10-K: $345M SPAC trust; seeking tech target

American Exceptionalism Acquisition Corp. A reported $348.4M in its trust following its $345M IPO, with no business combination yet and a 24–27 month window to close a deal.

Summary

• Completed a $345,000,000 IPO on September 29, 2025 (including full over-allotment), listing Class A shares on NYSE under ticker AEXA.
• Held $348,366,162 in the trust account at December 31, 2025 (approx. $10.10 per public share), invested in U.S. Treasury-focused instruments.
• Recorded 2025 interest income of $3,366,162 and a net loss of $7,197,255, primarily due to a $10,350,000 advisory fee expense accrual.
• Deferred underwriting fee payable totals $10,350,000; offering costs were $11,130,322 (including $250,000 cash underwriting fee).
• Private placement: 175,000 Class A shares sold to the sponsor for $1,750,000 at IPO close.
• Founder shares: 14,785,714 Class B held by sponsor and directors (including 300,000 transferred to two independent directors); over-allotment removal of potential forfeiture confirmed.
• Completion window: 24 months from the IPO closing (to September 29, 2027) or 27 months if a definitive agreement is signed within 24 months.
• Cash outside the trust was $515,931 with a working capital surplus of $635,125 as of year-end; no operations and no target announced.
• Governance: prior to the business combination, only Class B holders vote to appoint or remove directors; AEXA is considered a controlled company but is not currently relying on the exemption.
• As of March 30, 2026, 34,675,000 Class A and 14,785,714 Class B shares were outstanding; no material legal proceedings or control deficiencies were reported.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as neutral: cash-in-trust and full over-allotment are positives, offset by no announced target and sizable deal-contingent fees.

Positives

• Strong liquidity with $348,366,162 in the trust account at December 31, 2025, including interest.
• Full over-allotment exercised, raising the IPO total to $345,000,000 and validating demand.
• Interest income of $3,366,162 in 2025 offsets some costs while searching for a target.
• Founder shares convert to Class A only upon performance thresholds ($15.00/$17.50/$20.00) or change of control, which better aligns sponsor upside with public holders.
• Experienced sponsor and management team (affiliated with Social Capital; prior SPAC experience noted).
• Listed on NYSE with liquidity beginning September 26, 2025; no material legal proceedings disclosed.
• Adoption of a compensation recovery (clawback) policy on September 25, 2025 and an insider trading policy enhances governance.

Negatives

• Reported a net loss of $7,197,255 for the 2025 period driven by a $10,350,000 advisory fee expense accrual.
• Substantial deal-contingent obligations: $10,350,000 deferred underwriting fee plus a $10,350,000 advisory fee payable upon a successful business combination.
• Potential dilution from founder shares and possible equity-linked financing; anti-dilution could keep founders at 30% on conversion in certain issuance scenarios.
• Class B holders control director appointments until a business combination, reducing public shareholders’ influence pre-deal.
• Limited operating runway: must complete a deal by September 29, 2027 (or up to 27 months if conditions are met) or liquidate.
• Exposure to SPAC-specific risks such as high redemptions, financing uncertainty, potential PFIC status, and investment company rule considerations.

Risks

• Failure to complete a business combination within the completion window (24 months from IPO closing, or 27 months with a signed definitive agreement within 24 months) would trigger liquidation and return of funds to public shareholders.
• High redemptions and deferred underwriting fees may impair the ability to close the most desirable deal or to optimize capital structure.
• Potential PFIC status could result in adverse U.S. federal income tax consequences for U.S. investors.
• Risk of being deemed an unregistered investment company if trust assets remain in investment securities too long; the company may shift to bank demand deposits to mitigate.
• NYSE delisting risk if listing standards are not maintained, which could reduce liquidity and increase volatility.
• Conflicts of interest: sponsor, officers, and directors may have competing obligations and incentives, including founder-share economics.
• Regulatory scrutiny: new SEC SPAC rules (adopted January 24, 2024) increase disclosure and operational burdens, potentially raising costs and timing risks.
• Geopolitical, inflation, and market volatility could disrupt M&A markets or financing needed to complete a business combination.
• CFIUS or other regulatory reviews could delay, condition, or prevent a U.S. deal involving foreign ownership considerations.
• Target-company financial statement and internal control readiness may constrain the pool of viable targets and increase deal timing/costs.

Future Outlook

Plans to identify and acquire a disruptive technology-focused target within 24 months of the IPO closing (or up to 27 months if a definitive agreement is signed within 24 months). May use cash, equity, debt, or a mix, and could enter PIPE or backstop arrangements. If no deal is completed by the deadline, public shares will be redeemed and the company will wind up.

Management Comments

• Intends to pursue innovative technology companies that can help sustain U.S. global leadership and benefit from access to public capital markets.
• Leverages Social Capital’s network and experience to source proprietary deal flow and support value creation post-combination.
• Founder shares vest only upon share-price performance milestones or a change of control, intended to align sponsor incentives with public shareholders.

Industry Context

StockSavvy.ai notes that SPACs continue to face higher redemptions, increased regulatory scrutiny under the SEC’s 2024 SPAC rules, and tighter financing conditions. AEXA’s relatively large trust size ($345M) and experienced sponsor may improve target access, but timing, valuation and redemption dynamics remain key headwinds.

Comparison to Industry Standards

• Trust size: At $345M, AEXA is larger than many SPACs formed in 2023–2025 (often $100–300M), potentially broadening target scope and reducing financing risk versus smaller peers.
• Sponsor promote terms: Founder shares convert only upon achieving $15/$17.50/$20 share-price thresholds or change of control, which is more performance-based than traditional 20% promotes that vest at closing.
• Listing and liquidity: NYSE listing is standard among larger SPACs; trust invested in U.S. Treasuries/money market funds is consistent with peers’ investment policies.
• Cost structure: Combined $20.7M in deferred/advisory fees is material; similar-scale SPACs often carry $10–15M in deferred fees without an additional advisory fee, making AEXA’s cost stack on the higher side.
• Sponsor pedigree: The team cites prior experience across 10 SPACs with multiple completed business combinations; this compares favorably to newer sponsors lacking public-company transaction track records.

Corporate Governance

Legal Proceedings

• No material litigation or governmental proceedings disclosed.

Related Party Transactions

• Sponsor purchased 12,321,429 founder shares for $25,000 on July 25, 2025; an additional 2,464,285 founder shares were issued via share capitalization on September 25, 2025 (aggregate 14,785,714).
• Sponsor transferred 300,000 founder shares (150,000 each) to two independent directors on September 23, 2025.
• Sponsor purchased 175,000 private placement shares for $1,750,000 at IPO close.
• Unsecured promissory note from sponsor up to $2,000,000 (no balance outstanding at 12/31/2025); potential working capital loans up to $1,500,000 convertible into private placement shares at $10.00 per share.
• Due from Sponsor balance of $8,304 at December 31, 2025 for an invoice paid by the company.

Stakeholder Impact

• Shareholders: Redemption right at approximately $10.10 per public share as of year-end; potential dilution from sponsor shares and any equity financing tied to a business combination.
• Creditors: Trust account is intended to be insulated from general creditor claims, but residual risk exists; sponsor has agreed to certain indemnification under specified conditions.
• Governance: Class B holders control director appointments prior to business combination; public holders have limited pre-deal voting influence.
• Market: NYSE listing provides liquidity; delisting risk and high-redemption scenarios could affect trading dynamics.

Next Steps

• Source and negotiate an initial business combination within the 24–27 month completion window.
• Determine deal structure (shareholder vote or tender offer) and prepare required SEC disclosures.
• Manage investment company risk by potentially shifting trust assets to bank demand deposits as the 24-month anniversary approaches.
• Secure any required third-party financing (PIPE/backstop/debt) and address regulatory reviews (including any CFIUS considerations) if applicable.
• If no deal is completed by September 29, 2027 (absent extension conditions), redeem public shares and liquidate.

Key Dates

Recommendation

Pre-deal SPAC with substantial cash-in-trust and an experienced sponsor, but no identified target and a meaningful fee overhang; a neutral hold is warranted pending deal visibility and valuation.

Keywords

SPAC, AEXA, American Exceptionalism Acquisition Corp. A, Trust account, IPO, NYSE, Social Capital, Chamath Palihapitiya, Founder shares, Redemptions, Deferred underwriting, Advisory fee, Blank check company, PFIC, Investment Company Act